



ENLITIC, INC.

AI DRIVEN DATA MANAGEMENT FOR THE
GLOBAL HEALTHCARE IT SECTOR
(RADIOLOGY SUB-SECTOR)

TechKnow Investor Day Presentation

30th July 2024



Important Notice and Disclaimer

This presentation has been prepared by Enlitic, Inc. (Enlitic or the Company) to provide summary information about the Company and its associated entities as at the date of this presentation, and the information in this presentation remains subject to change without notice. The Company has no obligation to update or correct this presentation.

The presentation is for informational purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or the law of any other jurisdiction. The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) and is not intended to be used as the basis for making an investment decision.

No representation or warranty, express or implied, is made as to the currency, accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. None of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers (each a Limited Party) guarantees or makes any representations or warranties, express or implied, as to, or takes responsibility for, the currency, accuracy, reliability, completeness or fairness of this presentation or the information, opinions and conclusions contained in this presentation. The Company does not represent or warrant that this presentation is complete or that it contains all material information about the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any expenses, damages, costs or loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation, including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

None of the Company or any of the other Limited Parties act, or are responsible, as a fiduciary to you, your directors, officers, employees, affiliates, partners, representatives, consultants, agents, advisers, securityholders, creditors or any other person. You and each of the Company and the other Limited Parties expressly disclaim any fiduciary relationship. The Company and the other Limited Parties are relying on you complying with this important notice and disclaimer and on the truth and accuracy of the representations, warranties, undertakings and acknowledgments given by you.

This presentation may contain certain forward-looking statements, forecasts, estimates, projections and comments about future events, including the Company's beliefs, assumptions and expectations about the performance of its businesses and certain strategic transactions and the recovery of domestic and global airline booking levels. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "goals", "aims", "target" and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. A number of important factors, both known and unknown, could cause the Company's actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, and many of these factors are beyond the Company's control. As such, there can be no assurance that actual outcomes will not differ materially from these statements. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and their differences may be material. Any forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. As such, no undue reliance should be placed on any forward-looking statement, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the aftereffects of COVID-19 pandemic and certain geopolitical tensions. Past performance is not necessarily a guide to future performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. Nothing contained in this presentation, or any other information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. None of the Company or any other Limited Party makes any representation or warranty as to the accuracy of any forward-looking statements contained in this presentation. Forward looking statements speak only as at the date of this presentation, and the Limited Parties disclaim any obligations or undertakings to release any update of, or revisions to, any forward-looking statements in this presentation.

Financial information contained in this presentation (if any) is unaudited, unless otherwise stated, and is therefore subject to change. You should be aware that this presentation has been prepared at a time when the review of the financial information contained in the presentation has not been completed and, accordingly, the Company takes no responsibility for, and can provide no assurance as to the reliability of, any information relating to the financial condition and/or financial and operating performance of the Company. Recipients of this presentation are cautioned therefore to not place any reliance on the financial (or other) information included in the presentation. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A\$) unless otherwise stated.

Certain market and industry data (including industry forecasts, projections, market sizes, market shares and market positions) included in this presentation has been obtained from public filings, research, surveys or studies conducted by third parties, including industry and general publications, which has not been independently verified by the Company, as well as from the Company's own internal estimates and research. The Company cannot warrant or guarantee the adequacy, fairness, accuracy or completeness of such information. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions. There is no assurance that any of the industry or market forecasts, including management estimates, which are referred to in this presentation will be achieved. In addition, such data involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. In addition, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source.

This presentation may contain trademarks and trade names of third parties, which are the property of their respective owners. Third party trademarks and trade names used in this presentation belong to the relevant owners and use is not intended to represent sponsorship, approval or association by or with the Company.

OUR MISSION

Our Mission

Enlitic's mission is to revolutionise healthcare by leveraging AI and data, empowering evidence-based decision-making, enhancing research, and transforming healthcare delivery.

Industry Problems

Radiology departments are experiencing workflow and capacity challenges compounded by a **lack of data standardisation** that impacts data quality and stakeholders within the enterprise.

Staff within the radiology departments are experiencing **high rates of stress and burnout** resulting from increased workloads, increasing complexity of imaging studies and conflicting demands on time.



Enlitic Solution

The Enlitic solution is built upon a software framework, **creating a network between applications**. It houses an ecosystem that enables and supports the exchange of information or content between different interdependent applications.

The framework **facilitates communications** between modalities, Enlitic applications, Electronic Medical Records and PACS.


It features a host of AI-powered applications that enable **data standardisation, de-identification, anonymisation and workflow simplification**.



WHAT WE DO

ENLITIC CORE COMPETENCY

Illustrative Example



Tangible Benefit	Use Case	Description
Improve Radiologist Productivity	Hanging Protocols	Puts time back in the hands of the radiologist
	Dictation template	
	AI orchestration	
Billing Accuracy	Contrast detection	Identifies and prevents lost billing opportunities
	Anatomy detection	
Data Monetisation	Deidentification	Delivers commercial insights and facilitates the potential sale of highly valuable curated data
	Data Curation	
Operational Efficiencies	Scan times	Drives revenue opportunities via increased patient throughput and reduced admin
	Image orchestration	
H&S / Liability Mgmt	Dose monitoring	Tracks patient wellbeing / safety and reduces legal liability through correcting human errors
	Laterality conflicts	

NECESSITY FOR ENLITIC'S USE CASES

Improve Radiologist Productivity

Enlitic estimates that a medium sized health system can achieve an annual increase in revenues by up to c.\$1.2M p.a.¹

Inaccurate descriptions increase read times.

Ensign 2.0 corrects study and series descriptions to decrease study read time by ~30 seconds².

Identify Billing Discrepancies

Missing or erroneous intravenous contrast could be underbilled in the U.S. by c.\$2B p.a.

Incomplete and inaccurate data is one of the main causes of underbilling.

Ensign 2.0 reviews the imaging data to identify key procedure data discrepancies.

Data Value Realisation

Tempus AI generated c.\$169M from the licensing of data and other analytical services in oncology in FY23

Non-standardised data reduces efficiency and poses significant challenges for research

Ensign 2.0 standardises imaging data and increases data value.

Improve and Enhance Data Quality

15% of extremity studies have unclear laterality, exposing radiology in the U.S. to a potential annual liability of c.\$3.4B

Inaccurate laterality data increases risk and impacts care delivery.

Ensign 2.0 reviews the data to identify potential laterality conflicts.

Realise Operational Efficiencies

A 5-minute reduction in average MRI scan times is expected to yield \$250K per machine p.a.

Due to siloed, non-standardised data, healthcare organisations struggle to achieve cost savings.

Ensign 2.0's ability to standardise data helps them achieve it.

Healthcare generates 30% of the world's data and almost 90% of that healthcare data is Medical Imaging Data

1) Management estimates
2) Management estimates derived from real life client examples

COMMERCIALISING AN UNTAPPED OPPORTUNITY



Estimated large total serviceable market of US\$3.7bn^(1,2)



Large customer opportunity pipeline estimated at US\$100m in Total Contract Value⁽³⁾



3 commercialised products:
ENDEX™, ENCOG™ and ENSIGHT 2.0™



Under development:
New product ENCODE™ & additional use cases



Successful A\$21m equity capital raise in Dec '23



15 customer agreements signed to date



Strong strategic partnerships in key markets

Leading innovator in data standardisation for medical imaging

- 1) The number of hospitals and radiology reading rooms assumed are 14,751 at an average annual revenue of US\$252k. Investors should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions. The Company has obtained significant portions of this information from market research and commentary prepared by third parties.
- 2) No consideration for growth into Anonymization, Data Migration or Real-World-Evidence
- 3) Information based off Enlitic internal CRM database and corporate model as of Mar 25, 2024. There is no guarantee that any of these leads or opportunities will result in any contracted clients or contracted revenue.

GROWTH STRATEGIES

Enlitic expects growth opportunities for the Company will come through the five key areas described below:



CURRENT BUSINESS

- ✓ Pipeline of opportunities
- ✓ Direct and OEM sales force
- ✓ Early adopters and innovators



NEW CUSTOMERS



INCREASED VOLUMES

- ✓ Increasing volumes with existing customers
- ✓ Expansion within existing customers
- ✓ Implementations through OEM install base



NEW SOLUTIONS

- ✓ ENCODE Coding and billing discrepancy application
- ✓ Land & expand with existing customers
- ✓ New customers needing new solutions



REVENUE SHARING

- ✓ Revenue sharing data monetization strategy
- ✓ Coding/billing recouping lost revenue sharing model




M&A OPPORTUNITIES

- ✓ Monitor potential adjacent opportunities across new geographies, service capabilities and industry segments.
- ✓ Consider the merits of strategic bolt-on opportunities to accelerate growth.



SUMMARY



- AI and machine learning opportunities exist at all levels of the radiology workflow process and will be important in achieving efficiency improvements
- Growing customer opportunity pipeline valued at an estimated US\$100 million in Total Contract Value
- Partnerships with key channel partners that are supporting Enlitic's growth
- High quality and experienced board and executive management
- Continuous focus on accelerating development in new product offerings and expediting the commercialisation of these products



Questions?

